Yuko Matsunaga Selected Research

Cefiderocol

4/2022	Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
3/2022	Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
10/2021	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
10/2021	Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
1/2021	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
1/2021	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
1/2019	Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuko Matsunaga Research Topics

Disease

8	Asthma (Bronchial Asthma) 08/2013 - 01/2011
6	Inflammation (Inflammations) 08/2013 - 01/2011
6	Eosinophilia 08/2013 - 04/2011
5	Healthcare-Associated Pneumonia 04/2022 - 01/2021
4	Infections 04/2022 - 01/2019
4	Pneumonia (Pneumonitis) 10/2021 - 01/2021
3	Respiratory Hypersensitivity 02/2012 - 07/2011
2	Critical Illness (Critically Ill) 03/2022 - 10/2021
2	Urinary Tract Infections (Urinary Tract Infection) 01/2021 - 01/2021
2	Virus Diseases (Viral Diseases) 06/2012 - 01/2011
1	Anemia 03/2022
1	Sepsis (Septicemia) 01/2021
1	Sarcopenia 01/2019
1	Neoplasms (Cancer) 03/2014
1	Chronic Obstructive Pulmonary Disease (COPD) 11/2013
1	Anaphylaxis (Anaphylactic Shock) 02/2012
1	Hyperplasia 09/2011
1	Persistent Infection 05/2011
1	Retinoblastoma (Glioblastoma, Retinal) 11/2003
1	Adult-Onset Still's Disease 09/2003
1	Hyperferritinemia 09/2003
1	Hepatitis 09/2003
1	Liver Diseases (Liver Disease) 09/2003
1	Fever (Fevers) 09/2003
1	Abscess 08/2003
1	Pelvic Inflammatory Disease (Pelvic Inflammatory Diseases) 08/2003

Drug/Important Bio-Agent (IBA)

7	CefiderocolIBA 04/2022 - 01/2019
7	CytokinesIBA 03/2014 - 09/2003
5	Interleukin-13IBA 03/2013 - 01/2011
4	AllergensIBA 03/2013 - 04/2011
3	Carbapenems (Carbapenem Antibiotics)IBA 04/2022 - 01/2019
3	Cephalosporins (Cephalosporin Antibiotics)IBA 03/2022 - 01/2021
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2019
3	OvalbuminIBA 08/2013 - 07/2011
3	Double-Stranded RNA (RNA, Double Stranded)IBA 03/2013 - 07/2011
2	SiderophoresIBA 03/2022 - 10/2021
2	Meropenem (Merrem)FDA LinkGeneric 03/2022 - 01/2021
2	Chelating AgentsIBA 03/2022 - 09/2011
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2019
2	AcidsIBA 03/2013 - 07/2011
2	Interleukin-10 (Interleukin 10)IBA 06/2012 - 05/2011
2	AntigensIBA 09/2011 - 07/2011
2	Janus Kinase InhibitorsIBA 01/2011 - 01/2011
1	IronIBA 03/2022
1	Polymyxins (Polymyxin)IBA 01/2021
1	ORALIT (ORS)IBA 01/2019
1	Immunoglobulin A (IgA)IBA 03/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2014
1	Immunoglobulin G (IgG)IBA 03/2014
1	Immunoglobulin M (IgM)IBA 03/2014
1	Immunoglobulins (Immunoglobulin)IBA 03/2014
1	L-SelectinIBA 03/2014
1	C-Reactive ProteinIBA 03/2014
1	InterferonsIBA 03/2014
1	InterleukinsIBA 03/2014
1	Complement System Proteins (Complement)IBA 03/2014
1	E-SelectinIBA 03/2014
1	Cell Adhesion MoleculesIBA 03/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2014
1	Theophylline (Theon)FDA LinkGeneric 11/2013
1	Aminophylline (Carine)FDA LinkGeneric 11/2013
1	Histone Deacetylases (Histone Deacetylase)IBA 11/2013
1	Messenger RNA (mRNA)IBA 08/2013
1	Leukotriene B4 Receptors (Leukotriene B4 Receptor)IBA 08/2013
1	Prostaglandin D2IBA 03/2013
1	Leukotriene B4IBA 03/2013
1	LipidsIBA 03/2013
1	Monoclonal AntibodiesIBA 06/2012
1	Interleukin-6 (Interleukin 6)IBA 06/2012
1	Poly I-CIBA 06/2012
1	Immunoglobulin E (IgE)IBA 02/2012
1	ZincIBA 09/2011
1	Interleukin-4 (Interleukin 4)IBA 09/2011
1	ethylenediamine (ethylenediamine dihydroiodide)FDA Link 09/2011
1	Acetylcholine (Acetylcholine Chloride)FDA Link 09/2011
1	aluminum sulfate (alum)IBA 09/2011
1	N,N,N',N'- tetrakis(2- pyridylmethyl)ethylenediamineIBA 09/2011
1	Small Interfering RNA (siRNA)IBA 04/2011
1	alpha- cyano- (3,4- dihydroxy)- N- benzylcinnamideIBA 01/2011
1	Interferon LambdaIBA 01/2011
1	2- tert- butyl- 9- fluoro- 3,6- dihydro- 7H- benz(h)imidazo(4,5- f)isoquinoline- 7- oneIBA 01/2011
1	Janus KinasesIBA 01/2011
1	Cyclin DIBA 11/2003
1	Phosphotransferases (Kinase)IBA 11/2003
1	Retinoblastoma ProteinIBA 11/2003
1	Prednisolone (Predate)FDA LinkGeneric 09/2003
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 09/2003
1	Methylprednisolone FDA LinkGeneric 09/2003
1	Ferritins (Ferritin)IBA 09/2003

Therapy/Procedure

2	Therapeutics 01/2021 - 09/2003
1	Mechanical Ventilators (Ventilator) 01/2021
1	Intravenous Infusions 01/2021
1	Laparotomy 08/2003